Nivalis Therapeutics, Inc. (ALPN) Upgraded by Zacks Investment Research to Hold

Nivalis Therapeutics, Inc. (NASDAQ:ALPN) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Wednesday.

According to Zacks, “Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. It engages in the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders and other diseases. Alpine Immune Sciences Inc., formerly known as Nivalis Therapeutics, is based in Seattle, Washington. “

Other research analysts have also issued research reports about the stock. Ladenburg Thalmann Financial Services began coverage on shares of Nivalis Therapeutics in a research report on Thursday, July 27th. They set a “buy” rating and a $17.00 price objective for the company. ValuEngine lowered shares of Nivalis Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Wednesday, October 11th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $5.75.

Nivalis Therapeutics (ALPN) traded down $0.14 during trading on Wednesday, reaching $10.01. 97,100 shares of the company’s stock were exchanged, compared to its average volume of 57,511. Nivalis Therapeutics has a 52-week low of $7.20 and a 52-week high of $26.48.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at

A hedge fund recently bought a new stake in Nivalis Therapeutics stock. Sowell Financial Services LLC bought a new stake in Nivalis Therapeutics, Inc. (NASDAQ:ALPN) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 15,714 shares of the biotechnology company’s stock, valued at approximately $162,000. Sowell Financial Services LLC owned approximately 0.40% of Nivalis Therapeutics at the end of the most recent quarter.

About Nivalis Therapeutics

Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.

Analyst Recommendations for Nivalis Therapeutics (NASDAQ:ALPN)

Receive News & Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply